Search - tctmd.com

Displaying 101 - 120 of 409

Sort: Relevancy | Date

One in Three Overweight MI Patients May Benefit From Semaglutide

News Daily News

One in Three Overweight MI Patients May Benefit From Semaglutide

February 26, 2024

Efforts to Up PCSK9 Use Still Falling Short, Analysis Finds

News Daily News

Efforts to Up PCSK9 Use Still Falling Short, Analysis Finds

February 23, 2024

News Daily News

Low Bleeding Profile With Asundexian Seen in Pooled Analysis

February 13, 2024

MOST: Eptifibatide, Argatroban Don’t Improve on IV Thrombolysis Alone

News Conference News ISC 2024

MOST: Eptifibatide, Argatroban Don’t Improve on IV Thrombolysis Alone

February 08, 2024

Injectable Semaglutide Shortage Forces Physicians to Pivot

News Daily News

Injectable Semaglutide Shortage Forces Physicians to Pivot

February 05, 2024

Less Is More: Lp(a) Much More Atherogenic than LDL

News Daily News

Less Is More: Lp(a) Much More Atherogenic Than LDL

Michael O'Riordan

January 16, 2024

FDA: No Signs of Link Between GLP-1s and Suicidal Thoughts, Actions

News Daily News

FDA: No Signs of Link Between GLP-1s and Suicidal Thoughts, Actions

January 12, 2024

Top General Cardiology and CVD Prevention News of 2023

News Daily News

Top General Cardiology and CVD Prevention News of 2023

Yael L. Maxwell

January 03, 2024

TCTMD’s Top 10 Most Popular Stories for December 2023

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for December 2023

December 28, 2023

Top Endovascular News of 2023

News Daily News

Top Endovascular News of 2023

December 28, 2023

AHA Selects 2023’s Leading Cardiovascular Research

News Daily News

AHA Selects 2023’s Leading Cardiovascular Research

December 22, 2023

Who Benefits Most From Semaglutide and How Long Will That Take?

News Daily News

Who Benefits Most From Semaglutide and How Long Will That Take?

December 19, 2023

Lp(a) Appears Tied to Myocardial Fibrosis: Observational Data

News Daily News

Lp(a) Appears Tied to Myocardial Fibrosis: Observational Data

Yael L. Maxwell

December 13, 2023

Stopping Tirzepatide Leads to Rebound in Weight, Cardiometabolic Risk

News Daily News

Stopping Tirzepatide Leads to Rebound in Weight, Cardiometabolic Risk

December 12, 2023

No Safety Concerns Seen With Inclisiran in Large ORION Analysis

News Daily News

No Safety Concerns Seen With Inclisiran in Large ORION Analysis

Michael O'Riordan

December 06, 2023

Optimal Care Reported in Less Than Half of Adults With ASCVD

News Daily News

Optimal Care Reported in Less Than Half of Adults With ASCVD

Yael L. Maxwell

December 05, 2023

Asundexian’s Lack of Efficacy Sinks OCEANIC-AF

News Daily News

Asundexian’s Lack of Efficacy Sinks OCEANIC-AF

November 20, 2023

Mortality Risk Varies Among Patients With Very High LDL Levels

News Daily News

Mortality Risk Varies Among Patients With Very High LDL Levels

Michael O'Riordan

November 17, 2023

Large, Sustained Reductions in Lp(a) With Lepodisiran in Phase I Study

News Conference News AHA 2023

Large, Sustained Reductions in Lp(a) With Lepodisiran in Phase I Study

Michael O'Riordan

November 13, 2023

AZALEA-TIMI 71: Abelacimab Slashes Bleeds vs Rivaroxaban in AF, but Stroke Impact Unclear

News Conference News AHA 2023

NOW PUBLISHED - AZALEA-TIMI 71: Bleeds Plunge With Abelacimab vs Rivaroxaban in AF, but Stroke Impact Unclear

November 12, 2023

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.